Inspire Pharmaceuticals said its drug for cystic fibrosis, denufosol, was shown to improve the ability of patients to exhale compared to placebo in a six-month study, an announcement that drew cheers from Wall Street in the form of a 34.8 percent stock price boost. (BioWorld Today) Read More
